The successful immunogenicity and safety results of ETVAX® are presented at Vaccines for Enteric Diseases (VED) Oct 16-18 in Lausanne, Switzerland
Lausanne, Switzerland, Wednesday Oct 16
As a world leading company within diarrhoeal vaccine development, Scandinavian Biopharma is regularly invited to participate in global conferences that bring together renowned researchers and decision makers from the pharmaceutical industry, international authorities and global health organisations. Scandinavian Biopharma’s vaccine ETVAX® is rated as the most advanced vaccine in the world against diarrhoeal disease caused by ETEC. Today we will present the excellent results from multiple completed and on-going clinical trials of ETVAX® at Vaccines for Enteric Disease (VED) – a conference that addresses the diverse aspects of vaccines to counter human enteric diseases. In the light of global public health issues, enteric diseases are estimated to be the top cause of infectious morbidity and the second leading cause of infectious mortality worldwide.
The topic of ETVAX® will be initiated with a presentation by Dr. Firdausi Qadri, icddr,b in Dhaka, that will cover the successfully completed Phase I/II trial that was conducted in 495 Bangladeshi (45 adults and 450 children). The study confirmed the safety and strong immunogenicity of ETVAX® and was conducted as a collaborative effort between University of Gothenburg (UG), icddr,b, and the international non-profit global health organisation PATH.
Associate Professor Anna Lundgren from the University of Gothenburg will expand on Dr Qadri’s presentation by providing an insight in T cell responses induced by ETVAX® given with or without dmLT adjuvant, based on data from the Phase I/II study in Bangladesh and from studies in Swedish adults.
ETVAX® is currently in Phase IIb clinical trials to evaluate safety and protective efficacy in 743 Finnish travellers to Benin. The study results will be unblinded Q1 2020. During VED, Professor Anu Kantele, from University of Helsinki and Helsinki University Hospital, will present the study design and preliminary findings (before data has been unblinded).
Ann-Mari Svennerholm, MD Professor from UG, will wrap up the topic on ETVAX® with a presentation covering the methods on how to determine the immune responses against ETVAX® in infants. Professor Svennerholm and Lou Bourgeois from PATH will chair a session on ETEC vaccines trials at the VED conference.
Scandinavian Biopharma is sponsoring this important meeting where experts discuss strategies to prevent the enteric disease burden in the world. Scandinavian Biopharma will be represented by Björn Sjöstrand (CEO) and Nils Carlin (CSO).